CD8A and cancer: Ras drives immune checkpoint molecules on the surface of tumor cells to bind to homologous receptors on immune cells such as CD4+ T cells, CD8+ T cells and NK cells, thereby reducing the killing ability of cancer cells; it also leads to increased levels of PD-L1 and B7-H3 and promotes immune escape of tumor cells (78).